Condition category
Signs and Symptoms
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Falls are common and a major cause of concern in older people. A proven treatment to reduce the risk of falls is exercise, but many older people are unable to undertake enough exercise and if the exercise is not regular or the person stops doing it, the beneficial effects are lost. The benefit of exercise is that it improves muscle strength and stamina. This study will look at a drug, called perindopril, commonly used to treat high blood pressure that may be of benefit in improving muscle function, stability and muscle tiredness in older people at risk of falls. We will examine people’s stability, i.e. how much they tend to sway while standing, and their muscle strength before and after treatment with a 15-week course of the drug. If the drug does improve the patients’ stability and reduces their risk of falls it might be a useful and easy to prescribe therapy for people at risk of falls in future.

Who can participate?
Anyone aged over 65 years who has been assessed at a Medicine for the Elderly Falls clinic in the past 2 years in NHS Tayside, UK. They must have had at least one fall within the past 12 months.

What does the study involve?
Participants will be randomly allocated into two groups. One group will receive the drug and the other group will receive a dummy medication to see if there is a difference in these measurements between the two groups at the end of treatment. Participants will be asked to attend Ninewells hospital twice in a 16-20 week period. These visits will last for about two hours. Blood pressure, balance and leg strength will be measured. Participants will be asked to give a blood sample for further tests and will be given a diary to record any falls. The study nurse will also visit participants at home four times during this 16-20 week period. These home visits will take about 15 minutes. Blood pressure and some blood samples (5 ml, no more than a teaspoonful) will be checked on two further occasions when the nurse visits participants at home to ensure that the medication agrees with them. On the other two home visits the nurse will attend to give participants supplies of study drug. Some participants who consent to it will have a test to measure the strength with which their leg responds to a magnetic impulse applied to the nerve in their groin.

What are possible benefits and risks of participating?
We cannot promise the study will help individual participants but the information we get from this study will help improve the treatment of older people. Those who receive the drug may additionally improve their muscle function and balance. The drug rarely can cause an upset stomach, dizziness or kidney problems with increases in blood levels of potassium. We will monitor participants’ blood and blood pressure to minimise the risks. Standing on the balance platform with eyes closed or while reaching forward and sideways may make participants feel off balance. The optional test using the magnetic impulse on participants’ femoral nerve may feel unpleasant. They may experience a tingling feeling like when you have bumped your elbow on the funny bone. It lasts only a second or two and many older people have found it tolerable. Testing leg strength may lead to mild pain in your muscles and joints.

Where is the study run from?
The study is run from the Ageing and Health Department at Ninewells Hospital in Dundee, UK.

When is the study starting and how long is it expected to run for?
The study starts in August 2013 and recruitment is expected to run for two-and-a-half years.

Who is funding the study?
The study is funded by the Chief Scientist Office, The Scottish Government, UK.

Who is the main contact?
Dr Deepa Sumukadas
+44 (0)1382 383086

Trial website

Contact information



Primary contact

Dr Deepa Sumukadas


Contact details

Ageing & Health
Mailbox 1
Ninewells Hospital
United Kingdom
01382 383086

Additional identifiers

EudraCT number

2013-001677-24 number

Protocol/serial number


Study information

Scientific title

Do ACE inhibitors reduce postural instability in older people? Towards a novel approach to falls prevention


PreFACE study

Study hypothesis

Use of the ACE inhibitor, Perindopril, improves postural instability in older people. Postural instability is a phenotype of the risk of falls

Ethics approval

Approved by Scotland A Research Ethics Committee on 28th May 2013, REC Ref 13/SS/0086

Study design

Double blind randomised placebo controlled trial

Primary study design


Secondary study design

Randomised controlled trial

Trial setting

Not specified

Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Falls in the Elderly


This is a randomised double blind controlled trial where participants will be randomly assigned to either perindopril or a matched placebo (dummy) tablet. Following screening visit to check eligibility for the trial and to collect baseline data on leg strength, balance and safety measures participants will then be randomised to receive either 2mg of perindopril or placebo for 2 weeks. They will then have blood pressure checked, adverse events monitored and bloods checked to ensure there are no safety issues. Should all be well they will have their study medications increased to 4mg for the rest of the study period, a further 13 weeks. They therefore receive study medications for 15 weeks in total in this trial. At their final study visit their leg strength, balance and blood tests will be reassessed to determine if there are any changes from baseline.
During the study period they will be seen at home twice by a researcher who will check blood pressure and safety bloods. Should there be concerns with any possible side effects of the medication they will either have their study medication reduced to 2mg (if they previously tolerated that dose) or study medication will be stopped though they will be encouraged to attend for the planned 15 week end of trial visit.

Intervention type



Not Specified

Drug names


Primary outcome measures

The primary outcome measure will be the change in Anterio-Posterior (AP) sway between perindopril and placebo groups as measured at baseline and end of 15 weeks treatment.

Secondary outcome measures

1 Static postural stability measures: change in mediolateral sway, average sway velocity and total sway area after 15 weeks of treatment
2. Dynamic postural stability: To determine if there is change in Limits of Stability (LOS) after 15 weeks of treatment with perindopril compared to placebo
3. Quadriceps strength: To determine if there is a change in sometric Quadriceps Maximum Voluntary Contraction strength (QMVC) after 15 weeks of treatment with perindopril compared to placebo
4 Falls: To determine if there is any difference in falls rates, between the perindopril and placebo groups. This study is not powered to determine this accurately but such information will provide important safety information as well as providing preliminary data for powering a future study.
5. Magnetic femoral nerve stimulation (subset of participants who consent, only):
5.1. To determine if there is a change in the greatest Twitch tension generated in the Quadriceps (TwQ) using magnetic femoral nerve stimulation after 15 weeks of treatment with perindopril compared to placebo.
5.2. To determine if there is an improvement in Endurance and fatigue using repeated QMVC after 15 weeks of treatment with perindopril compared to placebo.

Overall trial start date


Overall trial end date


Reason abandoned


Participant inclusion criteria

1. Aged 65 years or over
2. One or more self-reported falls in previous 12 months
3. Been assessed at a Medicine for the Elderly Falls clinic in previous 2 years
4. Able to provide informed consent

Participant type


Age group




Target number of participants

80 treated

Participant exclusion criteria

1. Already taking ACE inhibitor (ACEi) or Angiotensin Renal Blocker (ARB)
2. Contraindication to ACE inhibitor use [previous intolerance; significant aortic outflow obstruction (peak gradient >30mmHg) serum potassium >5.0mmol/l; eGFR<30ml/hr; serum creatinine >170umol/l]
3. Patients who have stopped ACEi or ARB after specialist falls assessment in the last 6 months
4. Clinical diagnosis of heart failure or asymptomatic left ventricular systolic dysfunction
5. Systolic BP>160mmHg or <100mmHg at screening visit
6. Wheelchair bound
7. Clinical diagnosis of Parkinson’s disease
8. Current use of Nonsteroidal anti-inflammatory drugs (NSAIDs)
9. Patients who have participated in any other clinical drug trial within the previous 30 days will be excluded
10. Intolerance to lactose
11. Cognitive impairment precluding informed consent

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Ageing & Health
United Kingdom

Sponsor information


University of Dundee/NHS Tayside (UK)

Sponsor details

Tayside Medical Science Centre
Ninewells Hospital & Medical School
TASC Research & Development Office
Residency Block
Level 3
George Pirie Way
United Kingdom
+44 (0)1382 383890

Sponsor type




Funder type


Funder name

Chief Scientist Office, Scottish Government: Ref CZH/4/856

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes